Search

Displaying results 9091 - 9100 of 10000 in total
  1. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    PW2101 is a beta blocker intended for the treatment of hypertension and angina. … The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.

  2. Drug

    Mirococept

    go.drugbank.com/drugs/DB06492
    Experimental

    It is a truncated form of the human Complement Receptor 1 (CR1) linked to a unique Prodaptin™ construct that regulates the over-production of complement at the cell surface, which occurs in inflammation … Mirococept (APT070) is a complement inhibitor currently under development for treatment of rheumatoid arthritis and I/RI.

    Synonyms: myristoylated recombinant SCR1-3 of human complement reseptor type I
  3. Drug

    Velafermin

    go.drugbank.com/drugs/DB06493
    Investigational

    Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the regeneration and repair of the cells lining the gastrointestinal tract. … Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated

  4. Drug

    Furaprofen

    go.drugbank.com/drugs/DB06499
    Experimental

    Synonyms: alpha-Methyl-3-phenyl-7-benzofuranacetic acidCategories: Heterocyclic Compounds, 2-Ring
  5. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.

    Categories: Heterocyclic Compounds, 2-Ring
  6. Drug

    MLN2704

    go.drugbank.com/drugs/DB06513
    Investigational

    A Phase 1/2 trial (NCT00070837) evaluated the safety, dosage, and pharmacokinetics of MLN2704 in patients with metastatic androgen-independent prostate cancer.

  7. Drug

    AZD2315

    go.drugbank.com/drugs/DB06540
    Experimental

    The drug AZD2315, an immunosuppressant developed by AstraZeneca, was in Phase 1 clinical trials for the treatment of rheumatoid arthritis but was discontinued during this phase

    Synonyms: L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, ACETATE (1:2), L-ALANINAMIDE, N-(1-OXO-5-PHENYLPENTYL)-L-ALANYL-L-ARGINYL-L-ALANYL-(.ALPHA.S,3R)-3-AMINO-.ALPHA.-METHYL-2-OXO-1-PYRROLIDINEACETYL-L-ALANYL-L-ARGINYL-N-(4-(2-AMINO-2-OXOETHYL)PHENYL)-, DIACETATE
  8. Drug

    Astaxanthin

    go.drugbank.com/drugs/DB06543
    Investigational

    Astaxanthin is a keto-carotenoid in the terpenes class of chemical compounds. It is classified as a xanthophyll but it is a carotenoid with no vitamin A activity. … It may be found in fish feed or some animal food as a color additive.

    Mixtures: VitaHealth L-Glutathione Plus
  9. Drug

    MG98

    go.drugbank.com/drugs/DB06544
    Experimental

    MG98, a second-generation antisense oligodeoxynucleotide inhibitor of human DNMT1, was investigated in the completed clinical trial NCT00003890 for treating patients with advanced solid tumors.

  10. Drug

    Bivatuzumab

    go.drugbank.com/drugs/DB06550
    Investigational

    Bivatuzumab (previously BIWA 4) is a humanized monoclonal antibody against CD44 v6. [A31688,A31689]